1. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis
- Author
-
Donald E. Goodkin, Leah P. Dick, Jannelle Eckhardt, David C. Mohr, Lisa Bedell, Lorianne K. Masuoka, David Russo, and Arne C. Boudewyn
- Subjects
medicine.medical_specialty ,Multiple Sclerosis ,Treatment adherence ,Emotions ,Interviews as Topic ,03 medical and health sciences ,0302 clinical medicine ,Patient Education as Topic ,Humans ,Medicine ,030212 general & internal medicine ,High rate ,business.industry ,Multiple sclerosis ,Interferon-beta ,Patient retention ,medicine.disease ,Formal relationships ,Patient management ,Clinical trial ,Treatment Outcome ,Neurology ,Data Interpretation, Statistical ,Physical therapy ,Patient Compliance ,Secondary progressive multiple sclerosis ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
The purpose of this study was to examine the relationship between patient management strategies employed by study personnel, and patient retention and adherence to treatment in the first year of a Phase III clinical trial of interferon beta-1b for treatment of secondary progressive multiple sclerosis (MS). Study staff from each of 35 sites were interviewed regarding patient management practices. Sites which were rated as more empathetic, as instilling a sense of purpose in the patient, and promoting less formal relationships with patients had high rates of adherence to treatment. In addressing specific patient concerns, attention to patients' emotional status and patients' expectations of trial participation were related to better adherence.
- Published
- 1999
- Full Text
- View/download PDF